James C. Mulloy, PhD
Title
Associate Professor of Pediatrics in Experimental Hematology
Appointment
Associate Professor of Pediatrics, University of Cincinnati College of Medicine
Email
james.mulloy@cchmc.org
Phone
513-636-1844
Fax
513-636-3768
Credentials
BA: (Biology), cum laude, St. Anselm College, Manchester, New Hampshire, 1986
MS: (Microbiology), Rutgers University-University of Medicine and Dentistry, New Brunswick, New Jersey, 1989
PhD: (Microbiology), Rutgers University-University of Medicine and Dentistry, New Brunswick, New Jersey, 1992
Position History
2008-present: Associate Professor of Pediatrics, CCHMC, Division of Experimental Hematology, Leukemia Biology Program, Cincinnati OH
2007-present: Member, Graduate Program in Molecular and Developmental Biology, Cincinnati Children’s Hospital, Cincinnati OH
Member, Graduate Program in Molecular and Developmental Biology, Cincinnati Children’s Hospital, Cincinnati OH
2006-present: Member, Graduate Program in Cancer and Cell Biology, University of Cincinnati, Cincinnati OH
2003-2008: Assistant Professor of Pediatrics, CCHMC, Division of Experimental Hematology, Leukemia Biology Program, Cincinnati OH
2001-2003: Senior Research Scientist, Sloan-Kettering Institute, New York NY
1998-2001: Research Associate, Sloan-Kettering Institute, New York NY
1997-1998: NCI Biotechnology Fellow, Basic Research Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
1992-1997: Intramural Research Fellow, Laboratory of Tumor Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
1990-1992: Graduate Assistant, Department of Pathology, University of Medicine and Dentistry-Robert Wood Johnson Medical School, New Brunswick, New Jersey
1986-1990: Teaching Assistant, Department of Microbiology and Molecular Genetics, Rutgers University, New Brunswick, New Jersey
Awards and Honors
2001-2006: The Howard Temin Award, K01 CA90370-01 Research Grant , received from the National Cancer Institute, NIH
Research
Connect to Jim Mulloy's laboratory webpage
Research Grants and Contracts
Current
R21 DK071103-01A1 5/01/06 – 04/30/09
NIH, NIDDK
RUNX-fusion Target Genes in Normal and Leukemic Hematopoiesis
Role: Principal Investigator
R01 CA118319-01 4/15/06 - 02/28/11
NIH, NCI
The Role of CBFβ-MYH11 in Acute Myeloid Leukemia
Role: Principal Investigator
Pediatric Scientist Development Program (Ben Mizukawa) 07/01/08 – 06/30/10
Association of Medical School Pediatric Department Chairs
Characterization of Rac GTPases in Acute Myeloid Leukemia
(AML) and their Potential as Therapeutic Targets
Role: Co-Mentor
G&P Foundation for Cancer Research 06/01/08 – 5/31/11
Microenvironment and Flt3 Signaling in MLL Leukemia
Role: Principal Investigator
APRC Supplemental Award for R01 CA118319 07/01/08 – 06/30/10
NIH, NCI
Collaboration with Drs. Janet Rowley and Jianjun Chen
The Role of miRNAs in Cytogenetically Defined Acute Leukemia
Role: Principal Investigator
Hope Street Kids Fellowship (Kevin Link) 07/01/08 – 6/30/10
Targeting the FLT3 signaling pathway in MLL-AF9 leukemia
Role: Mentor
DOD PRO81404 (Saunthrarajah,Y.) 06/1/09-5/31/13
Department of Defense, Therapeutic Development Program
Next Generation DNMT1 Depleting Agents for Lekemia Therapy
Role: Co-investigator
Pending:
R01 CA 140518-01 (Mulloy, J.C.) 7/1/09-6/30/14
NIH,NCI
The Role of MLL-AF9 in Acute Myeloid Leukemia
Role: Principal Investigator
Publications, Most Recent
Connect to James Mulloy's publications on PubMed
Bosco,E.E., Mulloy,J.C., and Zheng,Y. Racl GRPase: A "Rac" of All Trades. Cell Mol Life Sci. 2009
Mulloy, J.C., Wunderlich,M., Zheng,Y., and Wei,J. Transforming Human Blood Stem and Progenitor Cells: A New Way Forward in Leukemia Modeling. Cell Cycle, 7(21): 57-52,2008.
Wei, J., Wunderlich, M., Fox, C., Alvarez, S., Cigudosa, J.C., Wilhelm, J.E., Zheng, Y., Cancelas, J.A., Gu, Y., Jansen, M., DiMartino, J.F. and Mulloy, J.C. Microenvironment Determines Lineage Fate in a Human Model of MLL-AF9 Leukemia. Cancer Cell. 2008 Jun;13(6):483-95.
Krejci, O., Wunderlich, M., Geiger, H., Schleimer, D., Jansen, M., Andreassen, P.R. and Mulloy, J.C. p53 signaling in response to increased DNA damage sensitizes AML1-ETO cells to stress-induced death. Blood. 111(4): 2190-2199, 2008
Wunderlich, M., Krejci, O., Wei, J., and Mulloy, J.C. Human CD34+ cells expressing the inv(16) fusion protein exhibit a myelomonocytic phenotype with greatly enhanced proliferative ability. Blood, 108(5)1690-1697, 2006.
Mulloy JC, Jankovic V, Wunderlich M, Delwel R, Cammenga J, Krejci O, Zhao H, Valk PJ, Lowenberg B, Nimer SD. AML1-ETO fusion protein up-regulates TRKA mRNA expression in human CD34+ cells, allowing nerve growth factor-induced expansion.Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4016-21.
Mulloy JC, Cammenga J, Berguido FJ, Wu K, Zhou P, Comenzo RL, Jhanwar S, Moore MA, Nimer SD. Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic element. Blood. 2003 Dec 15;102(13):4369-76.
Cammenga J, Mulloy JC, Berguido FJ, MacGrogan D, Viale A, Nimer SD. Induction of C/EBPalpha activity alters gene expression and differentiation of human CD34+ cells.Blood. 2003 Mar 15;101(6):2206-14.
Mulloy JC, Cammenga J, MacKenzie KL, Berguido FJ, Moore MA, Nimer SD. The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells.Blood. 2002 Jan 1;99(1):15-23.
Professional Organization Memberships
- American Association for Cancer Research
- American Association for the Advancement of Science
- American Society of Hematology
- International Society of Experimental Hematology
- International Society of Stem Cell Research
- Children's Oncology Group
Related Areas
This person works in these other areas at Cincinnati Children's Hospital Medical
Center:
